Literature DB >> 22942183

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

De-Chen Lin1, Tong Yin, Maya Koren-Michowitz, Ling-Wen Ding, Saskia Gueller, Sigal Gery, Takayuki Tabayashi, Ulla Bergholz, Julhash U Kazi, Lars Rönnstrand, Carol Stocking, H Phillip Koeffler.   

Abstract

Fms-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase with important roles in hematopoietic progenitor cell survival and proliferation. It is mutated in approximately one-third of AML patients, mostly by internal tandem duplications (ITDs). Adaptor protein Lnk is a negative regulator of hematopoietic cytokine signaling. In the present study, we show that Lnk interacts physically with both wild-type FLT3 (FLT3-WT) and FLT3-ITD through the SH2 domains. We have identified the tyrosine residues 572, 591, and 919 of FLT3 as phosphorylation sites involved in direct binding to Lnk. Lnk itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively activated FLT3-ITD. Both shRNA-mediated depletion and forced overexpression of Lnk demonstrated that activation signals emanating from both forms of FLT3 are under negative regulation by Lnk. Moreover, Lnk inhibited 32D cell proliferation driven by different FLT3 variants. Analysis of primary BM cells from Lnk-knockout mice showed that Lnk suppresses the expansion of FL-stimulated hematopoietic progenitors, including lymphoid-primed multipotent progenitors. The results of the present study show that through direct binding to FLT3, Lnk suppresses FLT3-WT/ITD-dependent signaling pathways involved in the proliferation of hematopoietic cells. Therefore, modulation of Lnk expression levels may provide a unique therapeutic approach for FLT3-ITD-associated hematopoietic disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22942183      PMCID: PMC3476541          DOI: 10.1182/blood-2011-10-388611

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.

Authors:  M Mizuki; R Fenski; H Halfter; I Matsumura; R Schmidt; C Müller; W Grüning; K Kratz-Albers; S Serve; C Steur; T Büchner; J Kienast; Y Kanakura; W E Berdel; H Serve
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  LNK mutations in JAK2 mutation-negative erythrocytosis.

Authors:  Terra L Lasho; Animesh Pardanani; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

3.  Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.

Authors:  Saskia Gueller; Helen S Goodridge; Birte Niebuhr; Hongtao Xing; Maya Koren-Michowitz; Hubert Serve; David M Underhill; Christian H Brandts; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2010-06-22       Impact factor: 4.962

4.  Expression and role of FLT3 in regulation of the earliest stage of normal granulocyte-monocyte progenitor development.

Authors:  Charlotta Böiers; Natalija Buza-Vidas; Christina T Jensen; Cornelis J H Pronk; Shabnam Kharazi; Lilian Wittmann; Ewa Sitnicka; Anne Hultquist; Sten Eirik W Jacobsen
Journal:  Blood       Date:  2010-04-14       Impact factor: 22.113

5.  Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.

Authors:  Saskia Gueller; Sina Hehn; Verena Nowak; Sigal Gery; Hubert Serve; Christian H Brandts; H Phillip Koeffler
Journal:  Exp Hematol       Date:  2011-03-01       Impact factor: 3.084

6.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

7.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.

Authors:  F Hayakawa; M Towatari; H Kiyoi; M Tanimoto; T Kitamura; H Saito; T Naoe
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

8.  APS, an adaptor protein containing PH and SH2 domains, is associated with the PDGF receptor and c-Cbl and inhibits PDGF-induced mitogenesis.

Authors:  M Yokouchi; T Wakioka; H Sakamoto; H Yasukawa; S Ohtsuka; A Sasaki; M Ohtsubo; M Valius; A Inoue; S Komiya; A Yoshimura
Journal:  Oncogene       Date:  1999-01-21       Impact factor: 9.867

9.  Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes.

Authors:  Chunaram Choudhary; Jesper V Olsen; Christian Brandts; Jürgen Cox; Pavankumar N G Reddy; Frank D Böhmer; Volker Gerke; Dirk-E Schmidt-Arras; Wolfgang E Berdel; Carsten Müller-Tidow; Matthias Mann; Hubert Serve
Journal:  Mol Cell       Date:  2009-10-23       Impact factor: 17.970

10.  Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.

Authors:  Chung Yeng Looi; Miki Imanishi; Satoshi Takaki; Miki Sato; Natsuko Chiba; Yoji Sasahara; Shiroh Futaki; Shigeru Tsuchiya; Satoru Kumaki
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

View more
  23 in total

1.  SH2B3: a new leukemia predisposition gene.

Authors:  Cheryl L Willman
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

Review 2.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

3.  The genomic landscape of nasopharyngeal carcinoma.

Authors:  De-Chen Lin; Xuan Meng; Masaharu Hazawa; Yasunobu Nagata; Ana Maria Varela; Liang Xu; Yusuke Sato; Li-Zhen Liu; Ling-Wen Ding; Arjun Sharma; Boon Cher Goh; Soo Chin Lee; Bengt Fredrik Petersson; Feng Gang Yu; Paul Macary; Min Zin Oo; Chan Soh Ha; Henry Yang; Seishi Ogawa; Kwok Seng Loh; H Phillip Koeffler
Journal:  Nat Genet       Date:  2014-06-22       Impact factor: 38.330

Review 4.  Grb10 is a dual regulator of receptor tyrosine kinase signaling.

Authors:  Nuzhat N Kabir; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316

5.  Suppressor of cytokine signaling 2 (SOCS2) associates with FLT3 and negatively regulates downstream signaling.

Authors:  Julhash U Kazi; Lars Rönnstrand
Journal:  Mol Oncol       Date:  2013-03-19       Impact factor: 6.603

Review 6.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

7.  Genetic loss of SH2B3 in acute lymphoblastic leukemia.

Authors:  Arianne Perez-Garcia; Alberto Ambesi-Impiombato; Michael Hadler; Isaura Rigo; Charles A LeDuc; Kara Kelly; Chaim Jalas; Elisabeth Paietta; Janis Racevskis; Jacob M Rowe; Martin S Tallman; Maddalena Paganin; Giuseppe Basso; Wei Tong; Wendy K Chung; Adolfo A Ferrando
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

8.  FLT3 signals via the adapter protein Grb10 and overexpression of Grb10 leads to aberrant cell proliferation in acute myeloid leukemia.

Authors:  Julhash U Kazi; Lars Rönnstrand
Journal:  Mol Oncol       Date:  2012-11-29       Impact factor: 6.603

9.  LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.

Authors:  Ying Cheng; Kudakwashe Chikwava; Chao Wu; Haibing Zhang; Anchit Bhagat; Dehua Pei; John K Choi; Wei Tong
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

Review 10.  SOCS proteins in regulation of receptor tyrosine kinase signaling.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Amilcar Flores-Morales; Lars Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2014-04-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.